Covered recipient · General Payments record
ABEL ALEX DONKA
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$1,846.58
- Reported across 133 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $242.90 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $211.93 | 15 |
| GlaxoSmithKline, LLC. | $17.71 | 1 |
| Janssen Pharmaceuticals, Inc | $13.26 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | $17.71 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116365331 | CMS |
| Janssen Pharmaceuticals, Inc | $13.26 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1077950592 | CMS |
| Novo Nordisk Inc | $13.51 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096948229 | CMS |
| Novo Nordisk Inc | $13.29 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096616488 | CMS |
| Novo Nordisk Inc | $10.28 | 02/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097618979 | CMS |
| Novo Nordisk Inc | $20.04 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096647470 | CMS |
| Novo Nordisk Inc | $3.96 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096713907 | CMS |
| Novo Nordisk Inc | $13.92 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096620070 | CMS |
| Novo Nordisk Inc | $23.37 | 07/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096918716 | CMS |
| Novo Nordisk Inc | $3.67 | 07/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097763516 | CMS |
| Novo Nordisk Inc | $15.89 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097459041 | CMS |
| Novo Nordisk Inc | $13.44 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097127779 | CMS |
| Novo Nordisk Inc | $17.39 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097603991 | CMS |
| Novo Nordisk Inc | $21.49 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096936803 | CMS |
| Novo Nordisk Inc | $12.28 | 11/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097014502 | CMS |
| Novo Nordisk Inc | $14.76 | 11/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096567644 | CMS |
| Novo Nordisk Inc | $14.64 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097606517 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.